In the antagonist protocol, several important advantages may be noted which include the following: in the polycystic ovarian syndrome (PCOS) patients, GnRH agonist can be used as a trigger in this protocol and reduce the risk of OHSS (7, 8). Here, GNRH1 is linked to polycystic ovary syndrome.